Protagonist Therapeutics, Inc. (PTGX)

USD 39.02

(-4.1%)

Market Cap (In USD)

2.32 Billion

Revenue (In USD)

60 Million

Net Income (In USD)

-78.95 Million

Avg. Volume

971.7 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
20.88-48.89
PE
-
EPS
-
Beta Value
2.163
ISIN
US74366E1029
CUSIP
74366E102
CIK
1377121
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Dinesh V. Patel Ph.D.
Employee Count
-
Website
https://www.protagonist-inc.com
Ipo Date
2016-08-11
Details
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.